MiNK Therapeutics (INKT) Set to Announce Quarterly Earnings on Tuesday

MiNK Therapeutics (NASDAQ:INKTGet Rating) will post its quarterly earnings results before the market opens on Tuesday, March 21st. Analysts expect MiNK Therapeutics to post earnings of ($0.21) per share for the quarter. Individual that are interested in participating in the company’s earnings conference call can do so using this link.

MiNK Therapeutics Trading Up 8.5 %

Shares of NASDAQ INKT opened at $2.17 on Tuesday. The company has a market cap of $73.32 million, a price-to-earnings ratio of -2.78 and a beta of -0.64. MiNK Therapeutics has a 12-month low of $1.09 and a 12-month high of $4.32. The stock’s 50 day simple moving average is $2.20 and its 200 day simple moving average is $2.30.

Institutional Trading of MiNK Therapeutics

An institutional investor recently bought a new position in MiNK Therapeutics stock. Vanguard Group Inc. purchased a new position in MiNK Therapeutics, Inc. (NASDAQ:INKTGet Rating) during the 3rd quarter, according to the company in its most recent Form 13F filing with the SEC. The firm purchased 49,107 shares of the company’s stock, valued at approximately $104,000. Vanguard Group Inc. owned about 0.15% of MiNK Therapeutics at the end of the most recent quarter. Institutional investors and hedge funds own 1.41% of the company’s stock.

MiNK Therapeutics Company Profile

(Get Rating)

MiNK Therapeutics, Inc, a clinical stage biopharmaceutical company, engages in the discovery, development, and commercialization of allogeneic, off-the-shelf, invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases. Its product candidate is AGENT-797, an off-the-shelf, allogeneic for iNKT cell therapy and treatment of various myeloma diseases, which is in Phase 1 clinical trials.

Read More

Earnings History for MiNK Therapeutics (NASDAQ:INKT)

Receive News & Ratings for MiNK Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MiNK Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.